Abstracts tagged "COVID-19"

Abstract Number: 0004 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries
Nelly Ziade¹, Lina El Kibbi², Ihsane Hmamouchi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Wafa Hamdi⁶, Fatemah Abutiban⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ³Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁷Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To evaluate the impact of the Coronavirus Disease 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases in…
Abstract Number: 0028 • ACR Convergence 2020
Pain in the Time of Corona: Impact of COVID 19 Outbreak on Fibromyalgia Patients
Valerie Aloush¹, Avital Gurfinkel², Noam Shachar³, Jacob Ablin¹ and Odelia Elkana⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Academic College TelAviv- Jaffa, Tel Aviv, Israel, ³Acamedic College Tel Aviv- Jaffa, Tel Aviv, Israel, ⁴Academic College Tel Aviv Jaffa, Tel Aviv, Israel
Background/Purpose: Fibromyalgia is a chronic pain disorder, characterized by abnormal pain processing in the central nervous system. Acute or chronic stress may trigger or aggravate…
Abstract Number: 0465 • ACR Convergence 2020
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
Rebecca Overbury¹, Gregory Stoddard² and Tracy Frech³, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Vaccinations are an important component of care in rheumatology as many patients are immunocompromised by treatment therapies. Patients are sometimes reticent to receive recommended…
Abstract Number: 0610 • ACR Convergence 2020
Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak
Kent Kwas Huston¹, Nehad Soloman², Janna Radtchenko³, Simon Helfgott⁴, Jasvinder Singh⁵ and Colin Edgerton⁶, ¹Kansas City Physician Partners, Kansas City, MO, ²Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ³Trio Health, Louisville, CO, ⁴BWH- HMS, Boston, MA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Patients (pts) with autoimmune diseases managed by rheumatologists represent vulnerable population with risk of serious complications if exposed to novel coronavirus SARS-CoV2. The first…
Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹ and Michael Ehrenstein², ¹University College London Hospital, London, United Kingdom, ²University College London, LONDON, United Kingdom
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Patricia Castro Pérez¹, Alberto Onteniente González¹, Angel Aragón Díez¹, Angel Gallegos Cid¹, Jesús Garcia-Arroba Muñoz¹ and Jose Manuel Rodriguez heredia¹, ¹Hospital de Getafe, Madrid, Spain
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…
Abstract Number: 0006 • ACR Convergence 2020
Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Milena Gianfrancesco¹, Liza Leykina², Zara Izadi³, Carly Harrison⁴, Suleman Bhana⁵, Wendy Costello⁶, Rebecca Grainger⁷, Jonathan Hausmann⁸, Jean Liew⁹, Emily Sirotich¹⁰, Paul Sufka¹¹, Zachary Wallace¹², Gabriela Schmajuk¹³, Pedro M Machado¹⁴, Philip Robinson¹⁵ and Jinoos Yazdany¹⁶, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴Lupus Chat, NA, ⁵Crystal Run Health, Middletown, ⁶Irish Children's Arthritis Network, Tipperary, Ireland, ⁷University of Otago, Wellington, New Zealand, ⁸Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁹University of Washington, Seattle, WA, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Healthpartners, St Paul, ¹²Massachusetts General Hospital, Newton, MA, ¹³University of California, San Francisco, Atherton, CA, ¹⁴University College London, London, United Kingdom, ¹⁵University of Queensland, Herston, Queensland, Australia, ¹⁶UCSF, San Francisco, CA
Background/Purpose: Individuals with rheumatic disease, particularly those on immunosuppressive medications, have a higher risk of developing severe infections. However, whether these patients experience more severe…
Abstract Number: 0050 • ACR Convergence 2020
Demographic Disparities in the Medically Underserved Populations of Southern California: A Rheumatology Cohort of Cytokine Release Syndrome Patients Due to COVID-19
Muntarin Karim¹, Patil Injean², Sandy Lee², Neha Chiruvolu³, Loomee Doo⁴, Deepa Panikkath², Donna Jose⁵, Micah Yu⁴, Anna Lafian⁴, Vaneet Sandhu⁶, Karina Torralba⁷, Christina Downey², Mehrnaz Hojjati⁴ and Marven Cabling⁴, ¹Loma Linda University Health System, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA, ³UC Riverside School of Medicine, Riverside, CA, ⁴Loma Linda University Medical Center, LOMA LINDA, CA, ⁵Loma Linda University Medical Center, Ontario, CA, ⁶Loma Linda University, Loma Linda, CA, ⁷Loma Linda University School of Medicine, Redlands, CA
Background/Purpose: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the present coronavirus disease (COVID-19) pandemic. Multiple epidemiologic reports across the country show…
Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Marianna Frey¹, Gregory Vitone², Candace Feldman³, Lindsay Lally¹, Anne Bass⁴, Jane Salmon¹, Mary Crow¹, Michael Lockshin⁵, Vivian Bykerk¹, Lisa Mandl¹ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Brigham and Women's Hospital, Boston, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
Abstract Number: 0613 • ACR Convergence 2020
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Kevin Kennedy¹, Emily Sirotich², Salman Surangiwala³, Maggie Larche², Mitchell Levine¹ and Jonathan Hausmann⁴, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…
Abstract Number: 0949 • ACR Convergence 2020
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Daimon Simmons¹, Hung Nguyen², Emma Gomez-Rivas³, YunJu Jeong⁴, William Apruzzese⁵, Edy Kim⁶ and Michael Brenner⁷, ¹Department of Pathology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital,, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, ⁵., Boston, ⁶Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…
Abstract Number: 1478 • ACR Convergence 2020
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
Juan C Sarmiento-Monroy¹, Gerard Espinosa², Fernanda Meira¹, Berta Caballol³, Maria C Londoño³, Sara Llufriu³, Aina Moll¹, Luis Fernando Quintana Porras¹, Felipe Julio Ramirez Garcia⁴, José Inciarte-Mundo¹, Elisabeth Solana¹, Yolanda Blanco¹, Eugenia Martinez¹, Victor Llorens¹, Sergio Prieto-González⁵, Georgina Espigol¹, Jose C Milisenda¹, Maria C. Cid⁵, Priscila Giavedoni¹, Jose M Mascaró¹, Isabel Blanco¹, Joan Albert Barbera¹, Oriol Sibila¹, Jordi Gratacos-Gines¹, Alfredo Adan², Alvaro Agustí¹, Raimon Sanmartí⁶, Julián Panés¹, Ricard Cervera¹, Jordi Vila¹, Alex Soriano¹, Jose Gómez-Puerta⁶ and On behalf INMUNOCOVID CLINIC⁷, ¹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²Hospital Clinic, Barcelona, Catalonia, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Hospital Clinic de Barcelona, Barcelona
Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…
Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Emily Sirotich¹, Kevin Kennedy², Salman Surangiwala³, Teresa Semalulu¹, Maggie Larche¹, Jean Liew⁴, Zachary Wallace⁵, Philip Robinson⁶, Rebecca Grainger⁷, Jeffrey Sparks⁸, Julia Simard⁹, Jinoos Yazdany¹⁰, Monique Gore-Massy¹¹, Richard Howard¹², Mitchell Levine² and Jonathan Hausmann¹³, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴University of Washington, Seattle, WA, ⁵Massachusetts General Hospital, Newton, MA, ⁶University of Queensland, Herston, Queensland, Australia, ⁷University of Otago, Wellington, New Zealand, ⁸Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁹Stanford Medicine, Stanford, CA, ¹⁰UCSF, San Francisco, CA, ¹¹Lupus Foundation of America, Brooklyn, NY, ¹²Spondylitis Association of America, Van Nuys, CA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…
Abstract Number: 0051 • ACR Convergence 2020
COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic
Shereen Mahmood¹, Laura Curiel-Duran², Ruchika Darapaneni², Dalynah Maldonado², Lindsay Pattison², Emilee Tu² and Tamar Rubinstein³, ¹Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY, ²Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: The novel coronavirus disease 2019 (COVID-19) pandemic has significantly affected all aspects of society, especially in the epicenters of New York City (NYC) and…
Abstract Number: 0467 • ACR Convergence 2020
Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab
Cathy Melong Pianta¹, Kim Lauper¹, Delphine Courvoisier¹, Tim Cunningham², Daniéle Allali³ and Axel Finckh⁴, ¹Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Private practice, Geneva, Geneva, Switzerland, ³Division of immunology, Geneva University Hospitals, Geneva, ⁴Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: The prevalence of anti-SARS-CoV-2 IgG infection was estimated at 9.7% in the Geneva population end of April 2020. (1) Immunosuppressed patients may be at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].